Drug Discovery

Engaging Biopharma and Government to Combat Resurgent Mpox
Research & Development Engaging Biopharma and Government to Combat Resurgent Mpox

Mpox has made a concerning comeback, compelling immediate and collaborative action. With an increased threat from the Clade Ib strain, the situation demands an effective response framework modeled after successful strategies used in the COVID-19 pandemic. This involves substantial input from both

Can MinervaX and Wacker Biotech Transform GBS Prevention?
Research & Development Can MinervaX and Wacker Biotech Transform GBS Prevention?

In a significant move for maternal and neonatal healthcare, Danish biotech company MinervaX has teamed up with German CDMO Wacker Biotech to develop a groundbreaking prophylactic vaccine for Group B Streptococcus (GBS) infections. This partnership marks a pivotal step in addressing a critical unmet

iTeos’ Belrestotug and Jemperli Combo Shows Promise in Lung Cancer Trial
Research & Development iTeos’ Belrestotug and Jemperli Combo Shows Promise in Lung Cancer Trial

The world of cancer treatment is ever-evolving, and recent developments have brought a glimmer of hope for those battling non-small cell lung cancer (NSCLC). iTeos Therapeutics has unveiled promising results from a mid-stage clinical trial examining the efficacy of combining their drug,

Can Centessa's New Drug Revolutionize Sleep Disorder Treatments?
Research & Development Can Centessa's New Drug Revolutionize Sleep Disorder Treatments?

Sleep disorders are a growing public health concern, impacting millions of individuals worldwide. Addressing these disorders effectively has long been a challenge for pharmaceutical companies. Enter Centessa Pharmaceuticals, a London-based biotechnology company that has made headlines with its

How Have Keytruda and Opdivo Transformed Cancer Treatment?
Research & Development How Have Keytruda and Opdivo Transformed Cancer Treatment?

In the evolving landscape of cancer treatment, the advent of immunotherapies Keytruda and Opdivo has marked a groundbreaking shift. Over the last decade, these drugs, known as PD1 inhibitors, have revolutionized oncology, offering new hope and significantly altering patient outcomes. Their story is

Recursion Confirms Safety of Experimental Drug REC-994, Efficacy Uncertain
Research & Development Recursion Confirms Safety of Experimental Drug REC-994, Efficacy Uncertain

Recursion Pharmaceuticals has reached a significant milestone in its journey to develop a treatment for cerebral cavernous malformation (CCM), a complex neurovascular condition. The company's leading experimental drug, REC-994, recently concluded a Phase 2 clinical trial, and the results are

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later